Tempest Therapeutics, Inc. TPST PHARMA

Q: What is the current share price of Tempest Therapeutics, Inc. (TPST)?

As of 2026-09-19 21:16 PDT, Tempest Therapeutics, Inc. (TPST) trades at $0.99 on NasdaqCM. Its 52-week range is $0.86 to $11.83.

Q: What is the market capitalisation of TPST?

Tempest Therapeutics, Inc. (TPST) has a market capitalisation of $16.37M on NasdaqCM.

Q: What is the P/E ratio of TPST?

TPST trades at a trailing price-to-earnings (P/E) ratio of -0.27. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 16.98.

Q: Is TPST a good stock to buy?

This page provides a data-driven analysis of Tempest Therapeutics, Inc. (TPST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.tempesttx.com

Company Profile ↓

$0.99

-89.43% 1Y

Mkt Cap$16.37M

P/E-0.27

P/B16.98

52W High$11.83

52W Low$0.86

Book Value$0.06

EPS (TTM)$-3.68

Company Overview

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

Growth & Price Performance

Stock Price Performance

1 Year:	-89.43%
6 Months:	-58.69%
3 Months:	-22.27%
1 Month:	+7.66%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 1% of range

$0.86 $11.83

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)43.84 · Neutral

Price Performance

1M+7.66%

3M-22.27%

6M-58.69%

1Y-89.43%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Trading 91.7% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.27

Industry PE

24.83

Forward P/E

-0.82

PEG Ratio

Book Value

$0.06

Price to Book

16.98

P/S

EV/EBITDA

-1.05

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

Revenue (YoY)

Earnings (YoY)

Profitability & Returns

ROCE

ROE

ROA

-79.37%

Profit Margin

0.00%

Op Margin

0.00%

Gross Margin

0.00%

EPS (Latest Qtr)

$-2.53

EPS (TTM)

$-3.68

Balance Sheet & Liquidity

Debt/Equity

9.55

Quick Ratio

0.17

Current Ratio

0.38

Debt

$7.56M

Total Assets

$10.75M

Current Assets

$2.45M

Working Capital

$4.96M

Ownership

Promoter Holding

31.78%

Chg in Prom Hold

FII / Inst Holding

29.57%

Chg in FII Hold

3.29%

Financial Snapshot

Enterprise Value

$16.37M

Total Revenue (TTM)

EBITDA

$-21.41M

Free Cash Flow

$-15.51M

Operating Cash Flow

$-20.73M

Shares Outstanding

16.54M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	TPST Tempest Therapeutics, Inc. PHARMA	0.99	-0.27	$16.37M	0.00%	-	-	-	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	84.00K	56.00K	-	81.00K	55.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.94M	7.97M	3.60M	4.08M	27.72M
Operating Income	-6.92M	-7.65M	-9.60M	-12.40M	-16.81M	-17.17M	-17.77M	-21.44M	-18.24M	-18.96M	-14.59M	-17.93M	-9.41M	-4.39M	-4.99M	-7.81M	-10.66M	-10.16M	-11.75M	-12.13M	-5.24M	5.43M	-5.13M	-6.79M	-7.74M	-	-8.16M	-8.77M	-8.77M	-7.58M	-7.47M	-6.59M	-7.97M	-9.58M	-10.55M	-10.94M	-7.97M	-3.60M	-4.08M	-27.72M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10.63M	-7.76M	-3.44M	-3.96M	-27.64M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	161.00K	46.00K	0	0	0
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10.86M	-7.87M	-3.51M	-4.02M	-27.70M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Net Income	-6.89M	-7.81M	-9.89M	-12.92M	-17.21M	-17.49M	-17.92M	-21.76M	-18.57M	-19.29M	-14.89M	-18.19M	-9.37M	-4.26M	-4.85M	-7.54M	-10.37M	-9.87M	-11.63M	-12.00M	-5.23M	-5.43M	-5.36M	-7.06M	-8.11M	-28.30M	-8.49M	-9.17M	-8.95M	-7.64M	-7.58M	-6.79M	-7.90M	-9.57M	-10.56M	-10.86M	-7.87M	-3.51M	-4.02M	-27.70M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10.55	-7.63	-1.21	-	-1.18	-0.79	-0.66	-0.55	-0.54	-0.48	-4.62	-5.52	-5.32	-41.08	-2.07	-0.79	-	-2.53
R&D Expense	3.26M	4.65M	4.53M	5.33M	5.75M	4.02M	4.00M	5.96M	5.99M	4.99M	5.76M	5.00M	4.02M	2.62M	2.39M	1.68M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	0	0	277.00K	653.00K	295.00K	-	-	-	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	34.64M	29.16M	42.03M	26.57M
Operating Income	-13.53M	-29.13M	-47.93M	-72.00M	-81.01M	-84.33M	-26.87M	-45.40M	-19.30M	-	-34.64M	-29.16M	-42.03M	-26.57M
EBITDA	-	-	-	-	-	-	-	-	-	-	-33.45M	-27.66M	-40.14M	-25.79M
Interest Expense	-	-	-	-	-	-	-	-	-	-	1.62M	1.45M	1.32M	207.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-35.71M	-29.49M	-41.84M	-26.26M
Tax Provision	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Net Income	-13.51M	-29.04M	-49.52M	-73.22M	-82.26M	-84.58M	-27.19M	-44.57M	-19.21M	-	-35.71M	-29.49M	-41.84M	-26.26M
Diluted EPS	-	-	-	-	-	-	-	-	-41.03	-	-40.17	-24.83	-19.50	-6.33
R&D Expense	6.32M	15.80M	21.78M	18.43M	21.64M	18.34M	-	-	-	-	-	-	-	-

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	4.58M	32.81M	47.55M	65.57M	138.61M	122.54M	19.81M	84.07M	74.97M	22.86M	-	46.09M	51.60M	41.49M	16.93M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	32.95M	40.36M	31.47M	8.27M
Cash & Equivalents	4.54M	14.78M	18.08M	6.41M	43.22M	43.93M	17.58M	73.29M	62.48M	18.82M	-	31.23M	39.23M	30.27M	7.71M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	15.00M	450.00K	0	-	-
Total Liabilities	762.00K	2.09M	5.84M	10.25M	11.76M	14.32M	4.83M	10.95M	15.10M	4.95M	-	27.98M	24.84M	22.36M	10.26M
Current Liabilities	675.00K	2.09M	5.77M	10.17M	11.24M	13.21M	4.09M	9.82M	12.52M	3.22M	-	7.28M	9.41M	14.22M	3.31M
Long Term Debt	-	-	-	-	-	-	599.00K	383.00K	168.00K	61.00K	15.07M	10.37M	6.26M	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	22.11M	20.66M	15.37M	8.14M
Total Equity	-2.38M	30.72M	41.70M	55.33M	126.85M	108.22M	-130.69M	70.95M	-50.36M	-68.79M	-	18.11M	26.77M	19.13M	6.67M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	809.12K	1.70M	3.38M	4.93M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-18.09M	-30.59M	-50.29M	-61.73M	-20.34M	-23.65M	-41.22M	-19.02M	-	-31.07M	-27.36M	-33.03M	-26.82M
Investing Cash Flow	-	-11.02M	-32.79M	-38.29M	8.29M	458.00K	1.93M	3.99M	-6.00K	-	-562.00K	-170.00K	-435.00K	0
Financing Cash Flow	-	32.41M	51.71M	125.39M	54.15M	-4.46M	77.74M	26.94M	34.60M	-	11.40M	35.60M	24.50M	4.26M
Capital Expenditure	-849.00K	-719.00K	-2.80M	-5.23M	-2.59M	-4.00K	-36.00K	-397.00K	-50.00K	-135.00K	-562.00K	-170.00K	-435.00K	-
Free Cash Flow	-	-18.81M	-33.39M	-55.52M	-64.32M	-20.34M	-23.68M	-41.62M	-19.07M	-	-31.63M	-27.53M	-33.46M	-26.82M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-20.23M	8.07M	-8.96M	-22.56M

Ratios (Annual)

Figures in %.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-25,992.4%	-12,406.1%	-28,585.1%	-	-	-	-	-	-	-	-
Net Margin %	-	-	-	-26,432.9%	-12,597.2%	-28,670.5%	-	-	-	-	-	-	-	-
ROE %	-44.0%	-69.6%	-89.5%	-57.7%	-76.0%	64.7%	-38.3%	88.5%	27.9%	-	-197.2%	-110.2%	-218.8%	-393.9%
ROCE %	-44.0%	-69.7%	-86.5%	-56.5%	-74.1%	-536.4%	-36.2%	-72.7%	-98.3%	-	-89.3%	-69.1%	-154.1%	-195.2%

Shareholding Pattern

Insiders

31.78%

Institutions

29.57%

Public Float

43.35%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Sabby Management, LLC	3.09%	511.29K	$494.92K
2	Versant Venture Management, LLC	1.63%	269.77K	$261.14K
3	Vanguard Capital Management LLC	1.41%	233.89K	$226.40K
4	Geode Capital Management, LLC	0.52%	86.62K	$83.85K
5	Vanguard Fiduciary Trust Co	0.42%	68.91K	$66.70K
6	Blackrock Inc.	0.24%	39.07K	$37.82K
7	Squarepoint Ops LLC	0.19%	30.90K	$29.91K
8	Northern Trust Corporation	0.12%	20.14K	$19.49K
9	Citadel Advisors Llc	0.12%	19.82K	$19.18K
10	UBS Group AG	0.03%	5.64K	$5.46K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TPST

Google News ue, 08 Sep 2026

A biotech CEO will speak Sept. 15; Tempest will archive the webcast - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPd3NKZ2RKTkoyVTFVcXB5VmdTZ1ZzWjVsd0RlLWVULWpPRnpKUV9LU3dQVlNwbUk5dDRXdEFCNnFLaGlFeFlJMGo0VWFPNGNlbnkxbklzMHJJNTVFZzRfcGJaRVhwVXV6elFtZW5wYkFkX05fbXcyRHg4MWhrcXVuRHRWRGhyc0pkTGczUU…

Google News Fri, 21 Aug 2026

Tempest Therapeutics (NASDAQ: TPST) lines up $50M stock facility that may heavily dilute holders - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxOdkFma2pUVVZaX1NxaTE5MkZmaWNWRkF0Rnhtb29kc1ZGaHpJal9TTkFqdzlrZ05NV2REbVV3ZVBFVEVhUVJqSE15aEVsQTNtQlVyMWF4NFg0aUg5bmthR1Rlc3c3QmpWZGphUk5EMkoxU0ZWYjRpaVBKeUpjVm1vd1pPY1c0bzVLcFJnd0…

Google News Wed, 27 May 2026

TPST - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE10Y1lmeElYdFBBY2dxQVZ2VkQxSkFiQ2JjTzJlMXRkc3lZUVNUT0pncl9CSlFqdkZ5TjRxTjhrUG5kWjI3WUE?oc=5" target="_blank">TPST</a>  <font color="#6f6f6f">Finviz</font>…

Google News Fri, 10 Apr 2026

Should I buy Tempest Therapeutics (TPST) - Zacks Investment Research

<a href="https://news.google.com/rss/articles/CBMibEFVX3lxTE9haXVWS3QtbnpQb29kMGZHWjNxSF9QYjdfVzkxaGtqaXRfcnNEZFJJSXRJckRwX05rWmlfbGdJbWRrdlhWRE52WkttUUozaS1oWWlNNGF4MEo0SGhVVU1jeG1qVzVYbUNFcm9vSg?oc=5" target="_blank">Should I buy Tempest …

Google News hu, 13 Aug 2026

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxONnhCUk9qSTdSMWpXX1YtYWZnQUE5UjdpaDhPU0k0eTVqbzBqb2V2bGVKZVZxWUV0R2VCTk5zQTg4R0I5THowbzJRWEw5TlRxNG5lcDNUU0kzYjFuLUV5MWtUcmtMUDhfeVRYa1YyaVF3Y3VHbHlEZWtyQWxTaExSR242WjJCSHZyNmVEVV…

Google News Wed, 19 Nov 2025

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiiAJBVV95cUxPc1oyN1pVck0yV3BqZ2oxWXkwRjJISDJTMUp6b1VfNm5PTnNENC1GNW5EbU9JT0RjMnZiTzl3RGxFYnFJTzRlU252aHR0VlFxMTZQSVpicHh1eFl2Yk10VTJDNzVpTGU0bnIwRXdaV1RJa3AwSkVGZjF2dGZPb2tRT0V4ZzNPbTg2dlNYbH…

TPST — Frequently Asked Questions

What is the current share price of Tempest Therapeutics, Inc. (TPST)?

As of 2026-09-19 21:16 PDT, Tempest Therapeutics, Inc. (TPST) trades at $0.99 on NasdaqCM. Its 52-week range is $0.86 to $11.83.

What is the market capitalisation of TPST?

Tempest Therapeutics, Inc. (TPST) has a market capitalisation of $16.37M on NasdaqCM.

What is the P/E ratio of TPST?

TPST trades at a trailing price-to-earnings (P/E) ratio of -0.27. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 16.98.

Is TPST a good stock to buy?

This page provides a data-driven analysis of Tempest Therapeutics, Inc. (TPST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Tempest Therapeutics, Inc. TPST PHARMA

Company Overview

Growth & Price Performance

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

A biotech CEO will speak Sept. 15; Tempest will archive the webcast - Stock Titan

Tempest Therapeutics (NASDAQ: TPST) lines up $50M stock facility that may heavily dilute holders - Stock Titan

TPST - Finviz

Should I buy Tempest Therapeutics (TPST) - Zacks Investment Research

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors - Quiver Quantitative

TPST Stock Plummets After Inking Deal To Acquire CAR-T Programs From Privately-Held Firm In All-Stock Transaction - Stocktwits

TPST — Frequently Asked Questions

What is the current share price of Tempest Therapeutics, Inc. (TPST)?

What is the market capitalisation of TPST?

What is the P/E ratio of TPST?

Is TPST a good stock to buy?

Explore More